This drug targets CD147 to block malaria parasite invasion of red blood cells, showing 100% protection in animal models (ED50 0.12 mg/kg) with efficacy lasting over 20 days. The product has completed Phase IIa clinical trials in Africa and is produced under cGMP standards using engineered cell lines, covering the entire process from cell culture to purification and freeze-drying. It complies with ICH and pharmacopoeia standards, offering a new solution for malaria prevention and treatment.

Technology provider:Military Medical University